All eyes on this Biotech stock with FDA Approval in the Works

Dear Reader,

This exciting new NASDAQ company trading at just under $5 that has caught our attention.

With its main early cancer detection product already approved and marketed in the EU, it's only a matter of time before the FDA gives the green light for availability in the US.

In fact, the company's biggest competitor experienced exponential growth after FDA approval in 2014, increasing its market cap from $400 million to nearly $12 billion.

This shows the incredible potential of FDA approval for pharmaceutical companies.

It's not just us who are excited about this opportunity, top analysts from HC Wainwright, JonesTrading, and Cantor Fitzgerald have all given this company a buy or overweight rating.

This is a clear sign that the company is poised for success.

Believe me when I tell you that you don't want to sleep on this stock.

Do your research and click here to get the name and symbol right now.

_______________________________________________________________________

Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Stockguru LLC 711 SW 24th Ave Boynton, Beach, FL 33435 This email is being sent from Investing Chatter. If you no longer wish to receive Investing Chatter emails, please click to unsubscribe.

DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.